Drug intelligence / Profile preview

Anti-CD19 UCAR-T cells

Development stage: Phase 1
Lead developer: Chongqing Precision Biotech Co., Ltd
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-CD19 UCAR-T cells are a universal chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen. This therapy involves a single intravenous infusion of engineered T-cells after lymphodepletion chemotherapy. It is being investigated for its safety and efficacy in treating refractory Juvenile Dermatomyositis (RJDM), with additional aims to characterize its pharmacokinetic and pharmacodynamic properties, assess its role in immune system reconstitution, and evaluate long-term survival benefits. The therapy is developed by Chongqing Precision Biotech Co., Ltd.

Other names: CD19 UCAR-T cellsCD-19 UCAR-T cellsCD 19 UCAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on Anti-CD19 UCAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-CD19 UCAR-T cells.

Explore the full profile